 | The topic of this article may not meet Misplaced Pages's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "Immuron" – news · newspapers · books · scholar · JSTOR (September 2023) (Learn how and when to remove this message) |
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases.. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea (TD) and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market.
External links
References
- "Anadis". Australian Stock Exchange. 5 June 2007.
- "About Us". immuron1. Retrieved 7 May 2022.
- "Immuron Limited - ABN, ACN, Business names, Former names". www.aubiz.net. Retrieved 7 May 2022.
- "IMMURON LIMITED - Australia Company". australia-corp.com. Retrieved 7 May 2022.
- Canada, Asia Pacific Foundation of. "Valeo Pharma, Baralex Sign Distribution Agreement with Australia's Anadis Ltd". Asia Pacific Foundation of Canada. Retrieved 18 September 2017.
 | This biotechnology article is a stub. You can help Misplaced Pages by expanding it. |
 | This pharmacy-related article is a stub. You can help Misplaced Pages by expanding it. |